John S Sack is a prominent inventor based in Lawrenceville, NJ (US), known for his significant contributions to the field of biotechnology. He holds a total of seven patents, showcasing his innovative work in developing therapeutic antibodies.

Latest Patents

Among his latest patents, Sack has developed isolated monoclonal antibodies that target human Cluster of Differentiation 73 (CD73) with high affinity. These antibodies inhibit the activity of CD73 and can mediate antibody-dependent CD73 internalization. The patents also include nucleic acid molecules encoding these antibodies, expression vectors, and host cells for their expression. Furthermore, Sack's inventions encompass immunoconjugates, bispecific molecules, and pharmaceutical compositions that utilize these antibodies. Notably, his work provides methods for inhibiting the growth of tumor cells expressing CD73, offering potential treatments for various cancers.

Career Highlights

John S Sack is associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts in the field of immunotherapy. His work has been instrumental in the development of novel therapeutic strategies aimed at combating cancer.

Collaborations

Sack has collaborated with notable colleagues in the industry, including Nils Lonberg and Alan J Korman, contributing to the advancement of antibody therapies.

Conclusion

John S Sack's innovative work in the development of antibodies against CD73 represents a significant advancement in cancer treatment. His contributions continue to impact the field of biotechnology and offer hope for improved therapeutic options.

This text is generated by artificial intelligence and may not be accurate.